Home › SEC Filings › Press Releases
Press Releases
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| PACB | PRESS-RELEASE | neutral | 4/10 | PacBio announced a multi-year strategic collaboration with Verily Health to integrate its HiFi long-read sequencing with | Oct 19, 2026 |
| RXRX | PRESS-RELEASE | mixed | 5/10 | Recursion Pharmaceuticals announced that Sanofi has optioned the first development candidate from their multi-program co | Oct 15, 2026 |
| RXRX | PRESS-RELEASE | bearish | 6/10 | Recursion Pharmaceuticals priced a $200 million underwritten public offering of 61.54 million shares at $3.25 per share, | Oct 15, 2026 |
| RXRX | PRESS-RELEASE | mixed | 6/10 | Recursion Pharmaceuticals announced a $200 million underwritten common stock offering alongside positive clinical data u | Oct 15, 2026 |
| PACB | PRESS-RELEASE | neutral | 4/10 | PacBio announced a collaboration with TychoBio, an AI drug discovery company, to generate full-length RNA data using Pac | Oct 6, 2026 |
| NTLA | PRESS-RELEASE | neutral | 2/10 | Intellia Therapeutics granted inducement stock awards to eight new employees under its 2024 Inducement Plan. This is a r | Oct 2, 2026 |
| FATE | PRESS-RELEASE | neutral | 2/10 | Fate Therapeutics announced management participation in Q4 2026 investor conferences. No financial results or material b | Oct 1, 2026 |
| BNGO | PRESS-RELEASE | bullish | 5/10 | Bionano Genomics highlighted three new peer-reviewed publications demonstrating that its optical genome mapping (OGM) te | Sep 14, 2026 |
| CRSP | PRESS-RELEASE | bullish | 7/10 | CRISPR Therapeutics presented one-year durability data from its Phase 1a trial of CTX310, an in vivo CRISPR/Cas9 gene ed | Aug 28, 2026 |
| FATE | PRESS-RELEASE | bullish | 5/10 | Fate Therapeutics announced first patient dosed in the Phase 2 potentially registrational RECLAIM-LN trial of FT819 for | Aug 14, 2026 |
| RXRX | PRESS-RELEASE | mixed | 6/10 | Recursion reported Q2 2026 revenue of $7.7M (well below $12.0M consensus) and a GAAP net loss of -$0.25/share (vs -$0.23 | Aug 5, 2026 |
| CRSP | PRESS-RELEASE | bullish | 6/10 | CRISPR Therapeutics reported Q2 2026 GAAP EPS of -$0.94, beating consensus of -$1.10 by 14.5%, as CASGEVY revenue reache | Aug 3, 2026 |
| NTLA | PRESS-RELEASE | bullish | 8/10 | Intellia presented additional positive Phase 3 HAELO data for lonvo-z (NTLA-2002) in HAE at EAACI 2026, with the manuscr | Jun 13, 2026 |
| FATE | PRESS-RELEASE | bullish | 6/10 | Fate Therapeutics presented early Phase 1 data for FT836, an off-the-shelf CAR T-cell therapy targeting MICA/B in solid | Jun 1, 2026 |
| NTLA | PRESS-RELEASE | neutral | 5/10 | Intellia Therapeutics announced that Phase 3 HAELO trial data for lonvo-z (NTLA-2002) in hereditary angioedema will be p | Jun 1, 2026 |
| RXRX | PRESS-RELEASE | neutral | 2/10 | Recursion Pharmaceuticals granted inducement RSU awards covering ~2.99 million shares to 33 new employees under its 2024 | May 29, 2026 |
| EDIT | PRESS-RELEASE | bearish | 8/10 | Editas Medicine priced a dilutive underwritten public offering of 55.6M shares and warrants at $2.25 per unit, raising ~ | May 26, 2026 |
| EDIT | PRESS-RELEASE | bearish | 6/10 | Editas Medicine announced an underwritten public offering of common stock (or pre-funded warrants) and accompanying warr | May 26, 2026 |
| EDIT | PRESS-RELEASE | bullish | 7/10 | Editas Medicine presented preclinical data for EDIT-401 at the EAS Congress, showing a single dose achieved ~90% mean re | May 26, 2026 |
| EDIT | PRESS-RELEASE | bullish | 5/10 | Editas Medicine presented preclinical data for EDIT-401 at ASGCT, showing ≥90% mean LDL-C reduction in NHPs durable thro | May 14, 2026 |
| BEAM | PRESS-RELEASE | bullish | 7/10 | Beam Therapeutics announced it will present updated biomarker data from the BEACON Phase 1/2 trial of ristoglogene autog | May 12, 2026 |
| FATE | PRESS-RELEASE | bullish | 7/10 | Fate Therapeutics presented clinical and preclinical data at ASGCT 2026 for its off-the-shelf iPSC-derived CAR T-cell pr | May 11, 2026 |
| RXRX | PRESS-RELEASE | mixed | 6/10 | Recursion Pharmaceuticals reported Q1 2026 EPS of -$0.21, beating consensus of -$0.26 by 18.3%, while revenue of $6.5M m | May 6, 2026 |
| EDIT | PRESS-RELEASE | bearish | 6/10 | Editas Medicine reported Q1 2026 EPS of -$0.26, slightly worse than the -$0.24 consensus (a miss), while revenue of $2.8 | May 5, 2026 |
| NTLA | PRESS-RELEASE | bearish | 6/10 | Intellia Therapeutics announced an underwritten public offering of $150 million in common stock, with an underwriter opt | Apr 27, 2026 |
| PACB | PRESS-RELEASE | neutral | 3/10 | PacBio announced that Lucid Genomics has joined its PacBio Compatible partner program, integrating its cloud-native bioi | Apr 21, 2026 |
| PACB | PRESS-RELEASE | neutral | 1/10 | PacBio announced it will report its Q1 2026 results on May 7, 2026. | Apr 16, 2026 |
| NTLA | PRESS-RELEASE | neutral | 2/10 | Intellia Therapeutics granted inducement RSUs covering 67,150 shares to 13 new employees outside its shareholder-approve | Apr 3, 2026 |
| RXRX | PRESS-RELEASE | neutral | 3/10 | Recursion Pharmaceuticals announced the appointment of Dr. Vicki Goodman as its new Chief Medical Officer, effective Apr | Mar 25, 2026 |
| BEAM | PRESS-RELEASE | bullish | 8/10 | Beam Therapeutics announced updated Phase 1/2 data for BEAM-302, a base-edited therapy for alpha-1 antitrypsin deficienc | Mar 25, 2026 |
Page 1 of 2 Next »